EGRX - Eagle Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Woodcliff Lake,
United States
Type: Equity
EGRX price evolution
EGRX
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $15.35 | $21.9 | $55.32 | $15.38 |
| Short term investments | ||||
| Net receivables | $115.14 | $114.95 | $72.44 | $96.93 |
| Inventory | $42.48 | $44.14 | $47.79 | $63.85 |
| Total current assets | $187.25 | $192.49 | $188.75 | $185.05 |
| Long term investments | ||||
| Property, plant & equipment | $1.01 | $1.12 | $1.17 | $1.3 |
| Goodwill & intangible assets | $152.44 | $157.91 | $163.36 | $150.58 |
| Total noncurrent assets | $217.57 | $221.68 | $217.41 | $201.4 |
| Total investments | ||||
| Total assets | $404.82 | $414.18 | $406.16 | $386.45 |
| Current liabilities | ||||
| Accounts payable | $15.84 | $17.11 | $18.99 | $13.21 |
| Deferred revenue | ||||
| Short long term debt | $8.3 | $7.5 | $6.25 | $34.96 |
| Total current liabilities | $86.63 | $97.81 | $111.09 | $121.83 |
| Long term debt | $61.9 | $68.83 | $56.22 | $26.43 |
| Total noncurrent liabilities | $66.15 | $73.52 | $61.51 | $32.84 |
| Total debt | $70.19 | $76.33 | $62.47 | $61.39 |
| Total liabilities | $152.78 | $171.33 | $172.6 | $154.67 |
| Shareholders' equity | ||||
| Retained earnings | $122.42 | $117.25 | $111.5 | $103.34 |
| Other shareholder equity | -$1.11 | -$1.11 | -$1.11 | $9.38 |
| Total shareholder equity | $252.04 | $242.84 | $233.56 | $231.78 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $55.32 | $97.66 | $103.16 | $109.78 |
| Short term investments | ||||
| Net receivables | $72.44 | $41.15 | $51.12 | $48 |
| Inventory | $47.79 | $21.91 | $8.07 | $6.57 |
| Total current assets | $188.75 | $172.61 | $166.06 | $179.45 |
| Long term investments | ||||
| Property, plant & equipment | $1.17 | $1.64 | $2.08 | $2.2 |
| Goodwill & intangible assets | $163.36 | $50.41 | $52.66 | $55.33 |
| Total noncurrent assets | $217.41 | $81.13 | $87.13 | $75.11 |
| Total investments | ||||
| Total assets | $406.16 | $253.73 | $253.19 | $254.55 |
| Current liabilities | ||||
| Accounts payable | $18.99 | $16.43 | $6.27 | $5.46 |
| Deferred revenue | ||||
| Short long term debt | $6.25 | $25.61 | $8 | $5 |
| Total current liabilities | $111.09 | $74.38 | $38.09 | $38.82 |
| Long term debt | $56.22 | $25.14 | $33.56 | |
| Total noncurrent liabilities | $61.51 | $2.9 | $29.09 | $36.56 |
| Total debt | $62.47 | $25.61 | $33.13 | $38.56 |
| Total liabilities | $172.6 | $77.28 | $67.18 | $75.38 |
| Shareholders' equity | ||||
| Retained earnings | $111.5 | $75.86 | $84.49 | $72.5 |
| Other shareholder equity | -$1.11 | -$0.09 | $0.1 | $0.14 |
| Total shareholder equity | $233.56 | $176.45 | $186.01 | $179.17 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $64.65 | $66.31 | $60.7 | $65.9 |
| Cost of revenue | $16.86 | $17.3 | $19.87 | $23.65 |
| Gross Profit | $47.79 | $49.01 | $40.83 | $42.25 |
| Operating activities | ||||
| Research & development | $9.83 | $9.27 | $7.22 | $9.33 |
| Selling, general & administrative | $27.65 | $27.96 | $24.15 | $23.46 |
| Total operating expenses | $37.48 | $37.23 | $31.37 | $32.79 |
| Operating income | $10.3 | $11.77 | $9.47 | $9.46 |
| Income from continuing operations | ||||
| EBIT | $10.75 | $11.75 | $15.28 | -$2.52 |
| Income tax expense | $4.13 | $4.48 | $5.14 | $3.47 |
| Interest expense | $1.45 | $1.52 | $1.98 | $1.15 |
| Net income | ||||
| Net income | $5.16 | $5.75 | $8.16 | -$7.13 |
| Income (for common shares) | $5.16 | $5.75 | $8.16 | -$7.13 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $316.61 | $171.55 | $187.8 | $195.89 |
| Cost of revenue | $94.94 | $42.18 | $45.47 | $60.9 |
| Gross Profit | $221.67 | $129.37 | $142.34 | $135 |
| Operating activities | ||||
| Research & development | $34.09 | $51.27 | $30.79 | $36.81 |
| Selling, general & administrative | $106.63 | $75.32 | $78.6 | $76.37 |
| Total operating expenses | $140.71 | $126.6 | $109.38 | $113.18 |
| Operating income | $80.96 | $2.77 | $32.95 | $21.82 |
| Income from continuing operations | ||||
| EBIT | $65.48 | -$2.91 | $25.25 | $24.68 |
| Income tax expense | $25.79 | $4.08 | $10.69 | $7.68 |
| Interest expense | $4.04 | $1.64 | $2.58 | $2.69 |
| Net income | ||||
| Net income | $35.64 | -$8.63 | $11.99 | $14.31 |
| Income (for common shares) | $35.64 | -$8.63 | $11.99 | $14.31 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Net income | $5.16 | $5.75 | $8.16 | -$7.13 |
| Operating activities | ||||
| Depreciation | $5.89 | $5.89 | $5.96 | $4.18 |
| Business acquisitions & disposals | $0 | $1.26 | ||
| Stock-based compensation | $4.19 | $4.64 | $4.12 | $3.54 |
| Total cash flows from operations | -$0.13 | -$33.51 | $37.56 | -$13.24 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.06 | -$0.01 | |
| Investments | -$12.5 | -$12.5 | ||
| Total cash flows from investing | -$0.01 | -$12.56 | -$0.01 | -$11.24 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$9.7 | |||
| Net borrowings | -$6.25 | $13.75 | $2.4 | $13 |
| Total cash flows from financing | -$6.41 | $12.65 | $2.39 | $3.3 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$6.54 | -$33.42 | $39.94 | -$21.18 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | $35.64 | -$8.63 | $11.99 | $14.31 |
| Operating activities | ||||
| Depreciation | $13.27 | $4.81 | $4.77 | $4.65 |
| Business acquisitions & disposals | -$74.15 | |||
| Stock-based compensation | $16.45 | $19.55 | $24.76 | $22 |
| Total cash flows from operations | $50.7 | $28.22 | $49.5 | $55.99 |
| Investing activities | ||||
| Capital expenditures | -$0.18 | -$0.32 | -$0.75 | -$0.78 |
| Investments | -$12.5 | -$5 | -$17.5 | |
| Total cash flows from investing | -$86.83 | -$5.32 | -$18.25 | -$0.78 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$16.26 | -$18.82 | -$31.34 | -$17.7 |
| Net borrowings | $11.4 | -$8 | -$5 | -$6.33 |
| Total cash flows from financing | -$6.21 | -$28.39 | -$37.87 | -$24.23 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$42.34 | -$5.5 | -$6.62 | $30.98 |
News
Fundamentals
| Market cap | $15.32M |
|---|---|
| Enterprise value | $70.16M |
| Shares outstanding | 13.09M |
| Revenue | $257.55M |
|---|---|
| EBITDA | $57.18M |
| EBIT | $35.26M |
| Net Income | $11.95M |
| Revenue Q/Q | -12.80% |
| Revenue Y/Y | -5.38% |
| P/E ratio | 1.28 |
|---|---|
| EV/Sales | 0.27 |
| EV/EBITDA | 1.23 |
| EV/EBIT | 1.99 |
| P/S ratio | 0.06 |
| P/B ratio | 0.06 |
| Book/Share | 19.33 |
| Cash/Share | 1.17 |
| EPS | $0.91 |
|---|---|
| ROA | 2.97% |
| ROE | 4.98% |
| Debt/Equity | 0.74 |
|---|---|
| Net debt/EBITDA | 2.40 |
| Current ratio | 2.16 |
| Quick ratio | 1.67 |